Chloramphenicol versus ampicillin plus gentamicin for community acquired very severe pneumonia among children aged 2-59 months in low resource settings: multicentre randomised controlled trial (SPEAR study)

被引:66
作者
Asghar, Rai [2 ]
Banajeh, Salem [3 ]
Egas, Josefina [4 ]
Hibberd, Patricia [5 ]
Iqbal, Imran [6 ]
Katep-Bwalya, Mary [7 ]
Kundi, Zafarullah [2 ]
Law, Paul [8 ]
MacLeod, William [1 ]
Maulen-Radovan, Irene [9 ]
Mino, Greta [10 ]
Saha, Samir [11 ]
Sempertegui, Fernando [4 ]
Simon, Jonathon [1 ]
Santosham, Mathuram [8 ]
Singhi, Sunit [12 ]
Thea, Donald M. [1 ]
Qazi, Shamim [13 ]
机构
[1] Boston Univ, Sch Publ Hlth, Ctr Int Hlth & Dev, Boston, MA 02118 USA
[2] Rawalpindi Gen Hosp, Rawalpindi, Pakistan
[3] Al Sabeen Hosp, Sanaa, Yemen
[4] Corp Ecuatoriana Biotecnol, Quito, Ecuador
[5] Tufts Univ, New England Med Ctr, Clin Res Inst, Boston, MA 02111 USA
[6] Nishter Hosp, Multan, Pakistan
[7] Univ Teaching Hosp, Lusaka, Zambia
[8] Johns Hopkins Bloomberg Univ, Dept Int Hlth, Baltimore, MD USA
[9] Inst Nacl Pediat, Div Invest, Mexico City, DF, Mexico
[10] Childrens Hosp, Guayaquil, Ecuador
[11] Dhaka Shishu Hosp, Dhaka, Bangladesh
[12] Postgrad Inst Med Educ & Res, Chandigarh 160012, India
[13] WHO, Dept Child & Adolescent Hlth & Dev, CH-1211 Geneva, Switzerland
来源
BMJ-BRITISH MEDICAL JOURNAL | 2008年 / 336卷 / 7635期
关键词
D O I
10.1136/bmj.39421.435949.BE
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To evaluate whether five days'treatment with injectable ampicillin plus gentamicin compared with chloramphenicol reduces treatment failure in children aged 2-59 months with community acquired very severe pneumonia in tow resource settings. Design Open label randonnised controlled trial. Setting Inpatient wards within tertiary care hospitals in Bangladesh, Ecuador, India, Mexico, Pakistan, Yemen, and Zambia. Participants Children aged 2-59 months with WHO defined very severe pneumonia. Intervention Chloramphenicol versus a combination of ampicillin plus gentamicin. Main outcome measures Primary outcome measure was treatment failure at five days. Secondary outcomes were treatment failure defined similarly among all participants evaluated at 48 hours and at 10 and 21 days. Results More children failed treatment with chloramphenicol at day 5 (16% v 11%; relative risk 1.43, 95% confidence interval 1.03 to 1.97) and also by days 10 and 21. Overall, 112 bacterial isolates were obtained from blood and lung aspirates in 110 children (11.5%), with the most common organisms being Staphylococcus aureus (n=47) and Streptococcus pneumoniae (n=22). In subgroup analysis, bacteraemia with any organism increased the risk of treatment failure at 21 days in the chloramphenicol group (2.09, 1.41 to 3.10) but not in the ampicillin plus gentamicin group (1.12, 0.59 to 2.13). Similarly, isolation of S pneumoniae increased the risk of treatment failure at day 21 (4.06, 2.73 to 6.03) and death (5.80, 2.62 to 12.85) in the chloramphenicol group but not in the ampicillin plus gentamicin group. No difference was found in treatment failure for children with S aureus bacteraemia in the two groups, but the power to detect a difference in this subgroup analysis was low. Independent predictors of treatment failure by multivariate analysis were hypoxaemia (oxygen saturation <90%), receiving chloramphenicol, being female, and poor immunisation status. Conclusion Injectable ampicillin plus gentamicin is superior to injectable chloramphenicol for the treatment of community acquired very severe pneumonia in children aged 2-59 months in low resource settings. Trial registration Current Controlled Trials ISRCTN39543942.
引用
收藏
页码:80 / 84
页数:7
相关论文
共 49 条
[1]   Oral amoxicillin versus injectable penicillin for severe pneumonia in children aged 3 to 59 months: a randomised multicentre equivalency study [J].
Addo-Yobo, E ;
Chisaka, N ;
Hassan, M ;
Hibberd, P ;
Lozano, JM ;
Jeena, P ;
MacLeod, WB ;
Maulen, I ;
Patel, A ;
Qazi, S ;
Thea, DM ;
Nguyen, NTV .
LANCET, 2004, 364 (9440) :1141-1148
[2]   A BACTERIOLOGICAL STUDY IN HOSPITALIZED CHILDREN WITH PNEUMONIA [J].
BAHL, R ;
MISHRA, S ;
SHARMA, D ;
SINGHAL, A ;
KUMARI, S .
ANNALS OF TROPICAL PAEDIATRICS, 1995, 15 (02) :173-177
[3]  
Bahwere P, 2001, Int J Infect Dis, V5, P180, DOI 10.1016/S1201-9712(01)90067-0
[4]   Where and why are 10 million children dying every year? [J].
Black, RE ;
Morris, SS ;
Bryce, J .
LANCET, 2003, 361 (9376) :2226-2234
[5]   Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controled trial [J].
Chintu, C ;
Bhat, GJ ;
Walker, AS ;
Mulenga, V ;
Sinyinza, F ;
Lishimpi, K ;
Farrelly, L ;
Kaganson, N ;
Zumla, A ;
Gillespie, SH ;
Nunn, AJ ;
Gibb, DM .
LANCET, 2004, 364 (9448) :1865-1871
[6]   Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae [J].
Deeks, SL ;
Palacio, R ;
Ruvinsky, R ;
Kertesz, DA ;
Hortal, M ;
Rossi, A ;
Spika, JS ;
Di Fabio, JL .
PEDIATRICS, 1999, 103 (02) :409-413
[7]  
Deivanayagam N, 1996, Indian Pediatr, V33, P813
[8]   Increase in sepsis due to multiresistant enteric gram-negative bacilli in Papua New Guinea [J].
Duke, T ;
Michael, A .
LANCET, 1999, 353 (9171) :2210-2211
[9]   Chloramphenicol versus benzylpenicillin and gentamicin for the treatment of severe pneumonia in children in Papua New Guinea: a randomised trial [J].
Duke, T ;
Poka, H ;
Dale, F ;
Michael, A ;
Mgone, J ;
Wal, T .
LANCET, 2002, 359 (9305) :474-480
[10]   HYPOXIA IN CHILDHOOD PNEUMONIA - BETTER DETECTION AND MORE OXYGEN NEEDED IN DEVELOPING-COUNTRIES [J].
DYKE, T ;
BROWN, N .
BRITISH MEDICAL JOURNAL, 1994, 308 (6921) :119-120